XAP THERAPEUTICS LIMITED

10613866
Active Cambridge

Activities of venture and development capital companies

38 employees website.com
Life sciences and medical technology Activities of venture and development capital companies
X

XAP THERAPEUTICS LIMITED

10613866

Activities of venture and development capital companies

Founded 10 Feb 2017 Active Cambridge, United Kingdom 38 employees website.com
Life sciences and medical technology Activities of venture and development capital companies

Previous Company Names

ROCKEND LIMITED 10 Feb 2017 — 20 Jul 2021
Accounts Submitted 7 Nov 2025 Next due 30 Sept 2026 3 months remaining
Confirmation Submitted 20 Feb 2026 Next due 23 Feb 2027 8 months remaining
Net assets £-15M £11M 2024 year on year
Total assets £7M £624K 2024 year on year
Total Liabilities £21M £10M 2024 year on year
Charges 3
2 outstanding 1 satisfied

Contact & Details

Contact

Registered Address

Babraham Research Campus Maia Building (B270) Cambridge CB22 3AT United Kingdom

Email

info@example.com

Website

www.example.com

Full company profile for XAP THERAPEUTICS LIMITED (10613866), an active life sciences and medical technology company based in Cambridge, United Kingdom. Incorporated 10 Feb 2017. Activities of venture and development capital companies. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type group
Next accounts 31 Dec 2025
Due by 30 Sept 2026 3 months remaining

Balance Sheet & P&L (2023–2024)

Cash in Bank

£4.13M

Increased by £785.21k (+23%)

Net Assets

-£14.76M

Decreased by £11.00M (-293%)

Total Liabilities

£21.50M

Increased by £10.38M (+93%)

Turnover

£82.19k

Increased by £38.49k (+88%)

Employees

38

Increased by 6 (+19%)

Debt Ratio

319%

Increased by 168 (+111%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
31 Dec Year End
2023
31 Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 3

Investors (5)

Investor NameInvestor SinceParticipating Rounds
Investor 3Apr 2021Seed
Investor 5Apr 2021Seed
Investor 1Feb 2022Seed

Share Capital

Share Capital

Share allotments and capital structure

33 Allotments 5,999,662 Shares £92.09m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
4 Dec 2025181,375£1.814£1.814
28 Nov 20252,745£0.027£0.027
7 Oct 20254,156£0.042£0.042
6 Oct 20257,000£0.07£0.07
6 Oct 20255,833£0.06£0.06

Officers

Officers

1 active 2 resigned
Status
Josephine Angela StevensSecretaryUnknownUnknown19 Jul 2022Active

Shareholders

Shareholders (32)

Sr One Capital Fund I Aggregator, Lp
49.0%
3,098,569
Amplitude Ventures Fund I, L.p
11.3%
711,888

Persons with Significant Control

Persons with Significant Control (0)

0 Active 3 Ceased

Rodger Novak

Ceased 19 Apr 2021

Ceased

Glaxosmithkline Finance Plc

Ceased 17 Sept 2020

Ceased

Shaun Patrick Foy

Ceased 19 Apr 2021

Ceased

Group Structure

Group Structure

No group structure identified

Charges

Charges

2 outstanding 1 satisfied

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
20 Feb 2026Confirmation StatementConfirmation statement made on 9 Feb 2026 with updates
12 Jan 2026CapitalAllotment of shares (GBP 63.19249) on 4 Dec 2025
12 Jan 2026CapitalAllotment of shares (GBP 61.37874) on 28 Nov 2025
21 Nov 2025CapitalAllotment of shares (GBP 61.35129) on 7 Oct 2025
7 Nov 2025AccountsAnnual accounts made up to 31 Dec 2024
20 Feb 2026 Confirmation Statement

Confirmation statement made on 9 Feb 2026 with updates

12 Jan 2026 Capital

Allotment of shares (GBP 63.19249) on 4 Dec 2025

12 Jan 2026 Capital

Allotment of shares (GBP 61.37874) on 28 Nov 2025

21 Nov 2025 Capital

Allotment of shares (GBP 61.35129) on 7 Oct 2025

7 Nov 2025 Accounts

Annual accounts made up to 31 Dec 2024

Recent Activity

Latest Activity

Confirmation statement made on 9 Feb 2026 with updates

4 months ago on 20 Feb 2026

Allotment of shares (GBP 63.19249) on 4 Dec 2025

5 months ago on 12 Jan 2026

Allotment of shares (GBP 61.37874) on 28 Nov 2025

5 months ago on 12 Jan 2026

Allotment of shares (GBP 61.35129) on 7 Oct 2025

7 months ago on 21 Nov 2025

Annual accounts made up to 31 Dec 2024

7 months ago on 7 Nov 2025